Attributes | Values |
---|
rdf:type
| |
Description
| - In this paper, we studied a designed series of aldose reductase (AR) inhibitors. The series was derived from a known AR binder, which had previously been shown to form a halogen bond between its bromine atom and the oxygen atom of the Thr-113 side chain of AR. In the series, the strength of the halogen bond was modulated by two factors, namely bromineMINUS SIGN iodine substitution and the fluorination of the aromatic ring in several positions. The role of the single halogen bond in ARMINUS SIGN ligand binding was elucidated by advanced binding free energy calculations involving the semiempirical quantum chemical Hamiltonian. The results were complemented with ultrahigh-resolution X-ray crystallography and IC50 measurements. All of the AR inhibitors studied were shown by X-ray crystallography to bind in an identical manner. Further, it was demonstrated that it was possible to decrease the IC50 value by about 1 order of magnitude by tuning the strength of the halogen bond by a monoatomic substitution. The calculations revealed that the proteinMINUS SIGN ligand interaction energy increased upon the substitution of iodine for bromine or upon the addition of electron-withdrawing fluorine atoms to the ring. However, the effect on the binding affinity was found to be more complex due to the change of the solvation/desolvation properties within the ligand series. The study shows that it is possible to modulate the strength of a halogen bond in a proteinMINUS SIGN ligand complex as was designed based on the previous studies of low-molecular-weight complexes.
- In this paper, we studied a designed series of aldose reductase (AR) inhibitors. The series was derived from a known AR binder, which had previously been shown to form a halogen bond between its bromine atom and the oxygen atom of the Thr-113 side chain of AR. In the series, the strength of the halogen bond was modulated by two factors, namely bromineMINUS SIGN iodine substitution and the fluorination of the aromatic ring in several positions. The role of the single halogen bond in ARMINUS SIGN ligand binding was elucidated by advanced binding free energy calculations involving the semiempirical quantum chemical Hamiltonian. The results were complemented with ultrahigh-resolution X-ray crystallography and IC50 measurements. All of the AR inhibitors studied were shown by X-ray crystallography to bind in an identical manner. Further, it was demonstrated that it was possible to decrease the IC50 value by about 1 order of magnitude by tuning the strength of the halogen bond by a monoatomic substitution. The calculations revealed that the proteinMINUS SIGN ligand interaction energy increased upon the substitution of iodine for bromine or upon the addition of electron-withdrawing fluorine atoms to the ring. However, the effect on the binding affinity was found to be more complex due to the change of the solvation/desolvation properties within the ligand series. The study shows that it is possible to modulate the strength of a halogen bond in a proteinMINUS SIGN ligand complex as was designed based on the previous studies of low-molecular-weight complexes. (en)
|
Title
| - Modulation of Aldose Reductase Inhibition by Halogen Bond Tuning
- Modulation of Aldose Reductase Inhibition by Halogen Bond Tuning (en)
|
skos:prefLabel
| - Modulation of Aldose Reductase Inhibition by Halogen Bond Tuning
- Modulation of Aldose Reductase Inhibition by Halogen Bond Tuning (en)
|
skos:notation
| - RIV/00216208:11310/13:10139922!RIV14-GA0-11310___
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - I, P(ED2.1.00/03.0058), P(GBP208/12/G016)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11310/13:10139922
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - noncovalent complexes; drug design; force-field (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Hobza, Pavel
- Kolář, Michal
- Matějíček, Pavel
- Veselý, Jan
- Fanfrlík, Jindřich
- Kamlar, Martin
- Cousido-Siah, Alexandra
- Hurný, David
- Lepsik, Martin
- Mitschler, Andre
- Munusamy, Elango
- Podjarny, Alberto
- Rezac, Jan
- Ruiz, Francesca X.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
http://localhost/t...ganizacniJednotka
| |